INTRODUCTION
============

Cellular senescence has been defined as a classic hallmark of the aging process. It can be triggered by various forms of stress, including telomere shortening, oncogenic activation, and reactive oxygen species (ROS), which induce DNA damage ([@ref1], [@ref2]). DNA damages result in the stabilization of p53 and subsequent overexpression of p21^Cip1/WAF1^, which then inhibits cell cycle progression. Therefore, it has been assumed that cellular senescence is a beneficial compensatory response that prevents the propagation of damaged and potentially tumorigenic cells ([@ref1], [@ref2]). Senescent cells can be identified by several molecular and cytological features, including retinoblastoma protein (RB) hypophosphorylation, SA-β-gal activity, the formation of senescence-associated heterochromatin foci, secretion of several inflammatory cytokines and chemokines, and upregulation of cell cycle arrest genes, such as p16^INK4A^, ARF, p53 and p21^Cip1/WAF1^ ([@ref3]-[@ref5]).

Previously, it has been reported that CK2 activity is downregulated in senescent IMR-90 human lung fibroblast cells, aged rat tissues, and aged nematodes ([@ref6], [@ref7]). Further, CK2 downregulation induces premature senescence in various human cells via activation of the ROS--p53--p21^Cip1/WAF1^ pathway ([@ref8], [@ref9]). Intracellular ROS homeostasis is maintained by the balance between the mechanisms that generate ROS and those that neutralize such toxic oxidants. The ROS detoxifying factors include Cu/Zn superoxide dismutase (SOD), MnSOD, catalase, glutathione S-transferase (GST), glutathione peroxidase 2 (GPX2), and glutathione reductase 1 (GSR1) ([@ref10], [@ref11]). We have shown that CK2 downregulation stimulates ROS accumulation via AKT-mediated inhibition of the antioxidant transcription factor FoxO3a. AKT-mediated phosphorylation of FoxO3a results in nuclear export of FoxO3a and thereby decreases transcription of FoxO3a target genes, such as Cu/ZnSOD, MnSOD, and catalase ([@ref12]). The transcription factor Nrf2 also participates in the maintenance of redox homeostasis in the cell. Nrf2 transcriptional response is mediated through the antioxidant response element (ARE) at the enhancer regions of its target genes, such as GST, GPX2, and GSR1 ([@ref13], [@ref14]). Nrf2 activity can be controlled by post-translational modifications. The best characterized mechanism for the regulation of Nrf2 activity is at the level of protein stability by Keap1, which is an adaptor protein for a Cul3-based ubiquitin E3 ligase. Under physiological conditions, Keap1 binds to and promotes the ubiquitination of Nrf2 in the cytoplasm, resulting in the proteasomal degradation of Nrf2. Under oxidative conditions, the ubiquitin E3 ligase activity of the Keap1--Cul3 complex declines. Consequently, Nrf2 is stabilized and translocates into the nucleus ([@ref14], [@ref15]).

In this study, we examined the role of Nrf2 in the ROS generation during CK2 downregulation-induced senescence. Our results suggest that CK2 downregulation inhibits the nuclear import of Nrf2 through decreasing AMPK activity and increasing Keap1 stability, consequently increasing ROS levels in cells.

RESULTS
=======

Overexpression of Nrf2 attenuates CK2 downregulation-induced upregulation of senescence markers and production of ROS in human cancer cells
-------------------------------------------------------------------------------------------------------------------------------------------

To investigate the involvement of Nrf2 in CK2 downregulation-induced senescence, MCF-7 and HCT116 cells were transfected with CK2α siRNA along with Nrf2 cDNA. As noted in previous reports ([@ref6], [@ref8], [@ref9]), CK2 downregulation upregulated senescence markers, such as p53 and p21^Cip1/WAF1^ levels and SA-β-gal activity. However, this effect was successfully suppressed in CK2-downregulated cells upon Nrf2 overexpression ([Fig. 1A and 1B](#F1){ref-type="fig"}). We then analyzed whether Nrf2 was involved in CK2 downregulation-induced ROS production. Knocking down CK2α increased ROS production as evaluated by CM-H~2~DCFDA staining. However, overexpression of Nrf2 antagonized the increase in ROS levels induced by CK2 downregulation ([Fig. 1C](#F1){ref-type="fig"}). Taken together, these results suggest that downregulation of Nrf2 is required for CK2 downregulation-induced ROS production and senescent phenotypes.

CK2 downregulation reduces Nrf2 protein level in human cancer cells
-------------------------------------------------------------------

To determine the role of CK2 in the regulation of Nrf2 activity, MCF-7 and HCT116 cells were transfected with an ARE-luciferase construct along with either the CK2α siRNA or pcDNA-HA-CK2α. CK2 downregulation decreased the activity of the luciferase reporter by approximately 30-50% compared with the control level. Conversely, the overexpression of CK2α increased the luciferase activity by approximately 20% ([Fig. 2A](#F2){ref-type="fig"}). It has been reported that Nrf2 regulates the expression of several antioxidant genes, such as *GST*, *GPX2*, and *GSR1* ([@ref13], [@ref14]). Our reverse transcription (RT)-PCR analysis also demonstrated that Nrf2 overexpression increased the *GST*, *GPX2*, and *GSR1* mRNA levels in the cells ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). To examine the effects of CK2 on the transcription of these Nrf2 target genes, cells were transfected with the CK2α siRNA or pcDNA-HA-CK2α. Whereas CK2α knockdown decreased the *GST*, *GPX2*, and *GSR1* mRNA levels, CK2α overexpression increased these mRNA levels ([Fig. 2B](#F2){ref-type="fig"}). Next, we examined whether CK2 regulated the expression of Nrf2. Immuno-blot analysis indicated that CK2α downregulation decreased the Nrf2 protein level in the cells. Conversely, the overexpression of CK2α increased the Nrf2 protein level ([Fig. 2C](#F2){ref-type="fig"}). Taken together, these results suggest that CK2 downregulation reduces Nrf2 protein levels, and consequently, the transcription of Nrf2 target genes decrease in human cancer cells.

CK2 increases autophagic degradation of Keap1 in human cancer cells
-------------------------------------------------------------------

To investigate the mechanism by which CK2 downregulation decreases Nrf2 protein level, CK2-downregulated cells were treated with the proteasome inhibitor MG132 (10 μM). The CK2 downregulation-induced decrease in Nrf2 was attenuated by the treatment with MG132, suggesting that CK2 downregulation stimulates proteasomal degradation of Nrf2 ([Fig. 3A](#F3){ref-type="fig"}). Because Keap1 promotes proteasomal degradation of Nrf2 and thus acts as a negative regulator of Nrf2 ([@ref14], [@ref15]), we examined whether CK2 regulated Nrf2 protein level via Keap1. As shown in [Fig. 3B](#F3){ref-type="fig"}, CK2α downregulation increased the Keap1 protein level in the cells, and the upregulation had the opposite effect. We then tested the role of autophagy in CK2-mediated Keap1 downregulation. Treatment with the autophagy inhibitors chloroquine (CQ, 100 μM), 3-methyladenine (3-MA, 1 mM), or ATG5 siRNA abolished the CK2 overexpression-induced downregulation of Keap1, suggesting that CK2 negatively controls Keap1protein level through autophagy ([Fig. 3C and 3D](#F3){ref-type="fig"}). Taken together, these data suggest that CK2 protects Nrf2 from proteasomal degradation via stimulating the autophagic degradation of Keap1.

CK2 downregulation reduces the nuclear localization of Nrf2 by inhibiting AMPK in human cancer cells
----------------------------------------------------------------------------------------------------

To examine the involvement of CK2 in the nuclear localization of NRF2, we separated cytoplasm and nuclei from the cells transfected with CK2α siRNA or pcDNA-HA-CK2α. More Nrf2 was found in the nuclear extracts than in the cytosolic extracts of the cells overexpressing CK2α. In contrast, less Nrf2 was observed in the nuclear extracts than in the cytosolic extracts of cells lacking CK2α, implying that CK2 downregulation inhibits the nuclear import of Nrf2 ([Fig. 4A](#F4){ref-type="fig"}). It has been reported that the α subunit of AMPK is phosphorylated at the T172 residue upon activation ([@ref16], [@ref17]), and AMPK acts as an upstream regulator of Nrf2 ([@ref18]). Thus, we examined the phosphorylation status of this residue by immuno-blot analysis to assess whether CK2 regulated the activity of AMPK. Whereas CK2 downregulation decreased the phosphorylation of the T172 residue of AMPK α subunit, CK2α overexpression had the opposite effect, indicating that CK2 induces AMPK activity ([Fig. 4B](#F4){ref-type="fig"}). To determine the role of AMPK in ARE-mediated transcription, cells expressing the ARE-luciferase reporter were treated with the AMPK activator AICAR. Treatment with AICAR (100 μM) completely abolished CK2 downregulation-induced reduction in the ARE-luciferase activity, suggesting that AMPK acts as a regulator of Nrf2 in senescent cells made by CK2 downregulation ([Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). We then investigated the role of AMPK in Nrf2 nuclear export induced by CK2 downregulation. As shown in [Fig. 4C](#F4){ref-type="fig"}, the CK2 downregulation-induced nuclear export of Nrf2 was attenuated by treatment with AICAR. Collectively, these results demonstrate that the AMPK-Nrf2 signaling pathway is suppressed during the cellular senescence induced by CK2 downregulation.

DISCUSSION
==========

CK2 downregulation has been shown to induce premature senescence in IMR-90 human lung fibroblast cells and in HCT116 and MCF-7 human cancer cells ([@ref6], [@ref8], [@ref9]). Additionally, *kin-10* (*C. elegans* ortholog of CK2β) knockdown induces the expression of age-related biomarkers in *C. elegans* ([@ref7]). CK2 downregulation increases ROS accumulation by downregulating FoxO3a and DAF-16 (*C. elegans* ortholog of FoxO3a) activity in human cells and *C. elegans*, respectively ([@ref12], [@ref7]), indicating that an increase in ROS levels plays an important role in CK2 downregulation-induced senescence and aging. The present study demonstrates that Nrf2 downregulation is associated with ROS generation during CK2 downregulation-mediated senescence in human cancer cells. In this study, Nrf2 overexpression abrogated the upregulation of CK2 downregulation-induced senescence markers (SA-β-gal staining and activation of p53--p21^Cip1/WAF1^) and ROS production ([Fig. 1](#F1){ref-type="fig"}). In addition, CK2 downregulation decreased the Nrf2 protein level and the mRNA levels of Nrf2 target genes (*GST*, *GPX2*, and *GSR1*) ([Fig. 2](#F2){ref-type="fig"}), suggesting that CK2 positively regulates Nrf2 activity.

The present results show that CK2 regulates Nrf2, at least, by two pathways. First, CK2 regulates the level of Nrf2 protein via Keap1. The present study demonstrated that CK2 downregulation-induced decrease in the Nrf2 protein was reversed by treatment with the proteasome inhibitor MG132 ([Fig. 3A](#F3){ref-type="fig"}). In addition, CK2 upregulation decreased the level of Keap1 protein, a component of Cullin-3-type ubiquitin ligase for Nrf2, and this event was suppressed by treatments with autophagy inhibitors (chloroquine, 3-methyladenine, or ATG5 siRNA) ([Fig. 3B-D](#F3){ref-type="fig"}). Taken together, these results suggest that CK2 reduces proteasomal Nrf2 degradation by stimulating the autophagic degradation of Keap1. Furthermore, reduction in Keap1 levels may allow accumulation of Keap1-free Nrf2 in the cytoplasm and consequently, Nrf2 translocates into the nucleus ([Fig. 4D](#F4){ref-type="fig"}). This conclusion is consistent with the results from previous reports have shown that the autophagy adaptor p62 directly interacts with Keap1, thereby directing Keap1 toward autophagic degradation ([@ref19], [@ref20]). Second, CK2 regulates the nuclear translocation of Nrf2 via AMPK. The present study found that CK2 downregulation inhibited the nuclear import of Nrf2 ([Fig. 4A](#F4){ref-type="fig"}). CK2 downregulation decreased the activity of AMPK, and treatment with the AMPK activator AICAR rescued CK2 downregulation-induced reduction in the Nrf2 activity ([Fig. 4B](#F4){ref-type="fig"} and [Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). Further, treatment with AICAR attenuated the CK2 downregulation-induced nuclear export of Nrf2 ([Fig. 4C](#F4){ref-type="fig"}), indicating that CK2 downregulation inhibits the nuclear import of Nrf2 by reducing the AMPK activity. Collectively, these results indicates that CK2 downregulation inhibits Nrf2 activity via both stabilization of Keap1 and inactivation of AMPK, consequently decreasing the intracellular antioxidant level, leading to ROS accumulation and cellular senescence ([Fig. 4D](#F4){ref-type="fig"}). We currently cannot explain how CK2 increases AMPK activity and autophagic degradation of Keap1. However, since senescent cells accumulate with age in various tissues and species, and have been observed in various age-related diseases ([@ref3],[@ref21]-[@ref23]), elucidating the molecular mechanism by which CK2 regulates the Keap1-Nrf2 axis will extend our understanding of organismal aging and contribute to the development of anti-senescence/aging therapies.

MATERIALS AND METHODS
=====================

Cell culture, RNA interference, and DNA transfection
----------------------------------------------------

MCF-7 human breast cancer cells and HCT116 human colon cancer cells (ATCC, Manassas, VA) were cultured in Dulbecco\'s Modified Eagle Medium containing 10% (v/v) fetal bovine serum under a humidified atmosphere of 5% (v/v) CO~2~ at 37°C. pcDNA3-EGFP-C4-Nrf2 and pcDNA3.1-HA-CK2α were transfected into cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as described by the manufacturer's instruction. ATG5siRNA (ATG5 HSS114104) was purchased from Invitrogen. siRNAs were transfected into cells using Polyfect (Invitrogen) for 48 h. The sequence of CK2α siRNA was 5'-UCAAGAUGACUACCAGCUGdTdT-3', and that of the negative control was 5'-GCUCAGAUCAAUACGGAGAdTdT-3'.

RT-PCR
------

Total RNA was extracted from HCT116 and MCF-7 cells and reverse transcribed using reverse transcriptase (Takara Bio Inc., Kyoto, Japan) and gene-specific reverse primers. The resulting cDNAs were PCR-amplified. The primers used for the assays are listed in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. PCR products were resolved on a 1.5% agarose gel. The RT-PCR bands were quantified using densitometry. *β-actin* RNA was used as an internal control to standardize the RNA amount in each sample.

Immuno-blotting
---------------

Antibodies against Nrf2, CK2α, p53, p21^Cip1/WAF1^, Keap1 and β-actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies specific for AMPK and phospho-AMPK (T172) were obtained from Cell Signaling Technology (Beverly, MA). Proteins were separated on 10% polyacrylamide gels in the presence of SDS, and then transferred onto nitrocellulose membranes. The membranes were blocked with 5% (w/v) non-fat, dried skim milk in TBST \[20 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.05% Tween 20\] for 2 h and then incubated with specific antibodies in 1% (w/v) non-fat, dried skim milk for 1 h. The membranes were washed three times with TBST, and then treated with the ECL system for the development of the signals (Amersham, GE Healthcare, Little Chalfont, UK). When deemed necessary, membranes were stripped with the stripping buffer \[2% SDS, 100 mM β-mercaptoethanol, and 50 mM Tris-HCl (pH 7.0)\] at 50°C for 1 h with gentle shaking and then re-probed with anti-β-actin antibody as an internal loading control.

SA-β-gal activity assay
-----------------------

Cells in sub-confluent cultures were washed with ice-cold phosphate-buffered saline (PBS), fixed with 3% (v/v) formaldehyde in PBS for 10 min at room temperature, and then incubated with a staining solution containing 1 mg/ml 5-bromo-4-chloro-3-indolyl β-D-galactoside, 40 mM citric acid-sodium phosphate (pH 6.0), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl, and 2 mM MgCl~2~ for 24 h at 37°C. Blue-stained cells were counted in at least 10 fields at 400 × magnification, and expressed as a percentage of positive cells.

Isolation of nuclear and cytoplasmic extract
--------------------------------------------

Cytoplasmic and nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Pierce, Rockford, IL) according to the manufacturer's instruction.

Dual-luciferase reporter assay
------------------------------

For the measurement of ARE activity, 1 × 10^4^ cells were transfected along with an ARE reporter vector (Promega, Korea) and phRL-TK Renilla luciferase vector (Promega) or inhibitor in a 96-well plate using Lipofectamine 2000 according to the manufacturer's protocol. After 24 h, firefly and *Renilla* luciferase activities were consecutively measured using the Dual-Luciferase Reporter Assay System (Promega).

Measurement of intracellular ROS levels
---------------------------------------

The oxidation-sensitive fluorescent probe CM-H~2~DCFDA (Invitrogen) was used to evaluate ROS levels. Cells were treated with 5 μM CM-H~2~DCFDA for 20 min at 37°C in the dark, detached by trypsinization, and then washed with PBS. Fluorescence intensity was determined with a Coulter Elite ESP Cell Sorter (Beckman Coulter Inc., Brea, CA). The forward and side scatter gates were set to exclude any dead cells from the analysis; at least 10,000 events within the gate were acquired per sample.

Statistical Analysis
--------------------

One-way analysis of variance testing of the data was performed using the SPSS package program (IBM, Armonk, NY). The results were considered significant if the P value was \< 0.05. Duncan's multiple-range test was performed if the differences between the groups were identified as α = 0.05.
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![Overexpression of Nrf2 attenuates the CK2 downregulation-induced ROS production and senescence phenotypes in human cancer cells. MCF-7 and HCT116 cells were transfected with CK2α siRNA in the absence or presence of the Nrf2 cDNA for 48 h. (A) Cells were lysed and electrophoresed on a 10% SDS--polyacrylamide gel. Protein bands were visualized by immunoblotting (left panel). Representative data from three independent experiments are shown. Graphs show the quantification of the protein levels relative to that of β-actin (right panel). (B) Cells were stained with 5-bromo-4-chloro-3-indolyl-β-D-galactoside, and the percentage of blue-stained cells was measured. (C) The cells were then incubated with 10 μM CM-H~2~DCFDA. Fluorescence intensity was determined by flow cytometry analysis (left panel). Representative data from three independent experiments are shown. The graphs show the relative fluorescence level (right panel). All data are presented as means ± SEM. \*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001.](BMB-53-272-f1){#F1}

![CK2 downregulation reduces the transcriptional activity and expression of Nrf2 in human cancer cells. (A) MCF-7 and HCT116 cells were co-transfected with the ARE luciferase construct and CK2α siRNA or pcDNA-HA-CK2α. The firefly luciferase activity was measured 24 h after transfection and normalized to *Renilla* luciferase activity. (B, C) Cells were transfected with CK2α siRNA or pcDNA-HA-CK2α for 48 h. (B) Total RNA was extracted from the cells, and RT-PCR was performed using specific primers. PCR products were resolved on a 1.5% agarose gel (upper panel). Graphs show the quantification of the mRNA levels of each gene relative to that of *β-actin* (bottom panels). (C) Cells were lysed and electrophoresed on a 10% SDS--polyacrylamide gel. Protein bands were visualized by immunoblotting (upper panel). Graphs show the quantification of the protein levels relative to β-actin levels (bottom panels). All data are shown as means ± SEM. \*P \<0.05; \*\*P \< 0.01; \*\*\*P \< 0.001.](BMB-53-272-f2){#F2}

![CK2 downregulation stimulates proteasomal degradation of Nrf2 via increasing Keap1 stability. (A) Cells were transfected with CK2α siRNA in the presence or absence of the proteasome inhibitor MG132 (10 μM). (B) Cells were transfected with CK2α siRNA or pcDNA-HA-CK2α for 48 h. (C, D) Cells were transfected with pcDNA-HA-CK2α in the presence or absence of the autophagy inhibitor chloroquine (CQ, 100 μM), 3-methyladenine (3-MA, 1 mM) (C), or ATG5 siRNA (D). Cells were lysed and electrophoresed on a 10% SDS--polyacrylamide gel. Protein bands were visualized by immunoblotting (upper panels). Graphs show the quantification of the protein levels relative to β-actin level (bottom panels). All data are shown as means ± SEM. \*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001.](BMB-53-272-f3){#F3}

![CK2 downregulation reduces the nuclear localization of Nrf2 through inhibiting AMPK in human cancer cells. (A) Cytoplasmic and nuclear fractions were isolated from the cells transfected with CK2α siRNA or pcDNA3.1-HA-CK2α and then both extracts were analyzed by immunoblotting (left panels). α-Tubulin (cytoplasmic marker) and histone H3 (nuclear marker) levels were quantified as loading controls. Graphs present the quantification of Nrf2 levels relative to the subcellular marker levels (right panels). (B) Cells were transfected with CK2α siRNA or pcDNA3.1-HA-CK2α for 48 h, lysed, and electrophoresed on a 10% SDS--polyacrylamide gel. Protein bands were visualized by immunoblotting (upper panel). Graphs show the quantification of the p-AMPK levels relative to AMPK level (bottom panel). (C) Cytoplasmic and nuclear extracts were isolated from the cells, and then both extracts were analyzed by immunoblotting (upper panels). The levels of α-tubulin (cytoplasmic marker) and histone H3 (nuclear marker) were quantified as loading controls. Graphs represent the quantification of Nrf2 levels relative to subcellular marker levels (bottom panels). All the data are shown as means ± SEM. \*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001. (D) Mechanistic model illustrating the involvement of Nrf2 in the CK2 downregulation-induced cellular senescence.](BMB-53-272-f4){#F4}
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